Aspect Biosystems at 2021 Virtual Cell & Gene Meeting on the Mediterranean
Vancouver, Canada, March 24, 2021 - Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. This is the second time that the company will be presenting at this conference. The Business Development Team from Aspect Biosystems will also be in attendance to participate in 1-on-1 partnering meetings. To arrange a meeting with them, search for “Aspect Biosystems” in the online partnering platform.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean is a four-day virtual conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.
The following are specific details regarding Aspect Biosystems’ presentation at the conference:
|Event||2021 Virtual Cell & Gene Meeting on the Mediterranean|
|Talk Title||Bioprinted Therapeutics: Next Generation Cell Therapy|
|Date||Tuesday, April 6 – Friday, April 9|
|Time||Company presentations will be available to view on-demand throughout the entirety of the conference|
Please visit www.meetingonthemed.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at firstname.lastname@example.org and interested media should contact Kaitlyn Dupont at email@example.com.
About Aspect Biosystems
Aspect Biosystems is a privately held biotechnology company combining its microfluidic 3D bioprinting technology with advanced biomaterials and cell biology to fuel medical research and the development of bioprinted therapeutics. Aspect is applying its technology platform internally to create implantable bioprinted therapeutics and partnering with leading researchers and industry innovators to bring these regenerative medicine solutions to the clinic. Learn more at www.aspectbiosystems.com.